Contact Us

Publications

These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.

These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)

Issa GC, et al.

J Clin Oncol. 2026 Jun 11:101200JCO2601159. Online ahead of print.

PMID: 42272166

CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials

Bourgeous W, et al.

Nat Commun. 2026 May 9. Online ahead of print.

PMID: 42103719

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Issa GC, et al.

J Clin Oncol. 2025 Jan;43(1):75-84.

PMID: 39121437

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Arellano ML, et al.

Blood. 2025 Aug 28;146(9):1065-1077.

PMID: 40332046

Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a KMT2A translocation in the United States

Abraham I, et al.

J Manag Care Spec Pharm. 2025 Jul;31(7):680-693.

PMID: 40459635

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Zeidner JF, et al.

J Clin Oncol. 2025 Aug 10;43(23):2606-2615.

PMID: 40504618